H Beyer, MD
Endocrinology, Diabetes & Metabolism · Fort Wayne, INNPI 1518915800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,014 of the $7,236 with a category attached, or 69.3%. 39 manufacturers reported payments, led by Medtronic at 36.1% of the total. 2025 is the largest year on record at $2,581, 8.9 times the $290 reported in 2019.
Across 218 payments — averaging $33.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$747
- Lilly USA, LLC$607
- Abbott$558
- Amgen$392
- AstraZeneca$208
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,88526%
- Food & beverage$5,01469%
- Education$3375%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $2,613 |
| Novo Nordisk | 44 | $747 |
| Lilly USA, LLC | 24 | $607 |
| Abbott | 18 | $558 |
| Amgen | 12 | $392 |
| AstraZeneca | 5 | $208 |
| Sanofi-aventis U.S. LLC | 11 | $194 |
| Enterra Medical, Inc. | 1 | $190 |
| Bayer | 5 | $159 |
| Esteve Pharmaceuticals LLC | 1 | $124 |
| Pfizer | 8 | $120 |
| Neurocrine Biosciences, Inc. | 4 | $118 |
| Tandem Diabetes Care, Inc. | 7 | $107 |
| Madrigal Pharmaceuticals | 4 | $98 |
| Novartis | 5 | $87 |
| AbbVie | 5 | $86 |
| Kyowa Kirin, Inc. | 4 | $79 |
| Recordati_rare_diseases_inc. | 4 | $75 |
| Mannkind Corporation | 3 | $73 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $61 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Chiesi USA, Inc. | 2 | $44 |
| Insulet Corporation | 2 | $39 |
| Boehringer Ingelheim | 2 | $34 |
| EUSA Pharma (US) LLC | 2 | $32 |
| Amryt Pharma Holdings Ltd | 2 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Alvogen Inc | 1 | $20 |
| Gilead | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Alcresta Therapeutics, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,932
- INPEN SMART INSULIN DELIVERY SYSTEM$257
- METOPIRONE$124
- FreeStyle Libre Pro$123
- Saxenda$122
- MOUNJARO$122
- TEPEZZA$121
- ZEPBOUND$116
- Kerendia$107
How this compares
$7,236 in reported general payments places this provider in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 12 | $1,253,023 |
| OzempicSemaglutide | 499 | $676,925 |
| MounjaroTirzepatide | 220 | $279,942 |
| Teriparatide | 24 | $109,461 |
| ProliaDenosumab | 52 | $91,695 |
| JardianceEmpagliflozin | 57 | $83,832 |
| TrulicityDulaglutide | 23 | $40,400 |
| Nutropin Aq NuspinSomatropin | 18 | $22,813 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 51 | $22,189 |
| FarxigaDapagliflozin Propanediol | 18 | $21,369 |
| Humalog Kwikpen U-100Insulin Lispro | 63 | $19,536 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $19,312 |
| Novolog FlexpenInsulin Aspart | 83 | $19,032 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 47 | $16,093 |
| GenotropinSomatropin | 11 | $14,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $208 | $1,274,39230 claims |
| Novo NordiskOzempic | $747 | $676,925499 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $607 | $328,027271 claims |
| Alvogen IncTeriparatide | $20 | $109,46124 claims |
| AmgenProlia | $392 | $91,69552 claims |
| Boehringer IngelheimJardiance | $34 | $83,83257 claims |
| PfizerGenotropin | $120 | $14,78711 claims |
| AbbVieSynthroid | $86 | $8,643100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Fort Wayne
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.